Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I and II surveys

Diabetologia

Volumn 47, Issue 7, 2004, Pages 1257-1265

  Pyoraia K ^a   Lehto, S ^a   De Bacquer, D ^b   De Sutter, J ^b   Sans, S ^c   Keil, U ^d   Wood, D ^e   De Backer, G ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b GHENT UNIVERSITY   (Belgium)

^c INSTITUT CATALÀ DE LA SALUT   (Spain)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Blood pressure; Cardiovascular agents; Cholesterol; Coronary disease; Diabetes mellitus; Obesity; Risk factors; Smoking

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERVIEW; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 4143134423     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1438-z     Document Type: Article

References (38)

1. Krolewski AS, Kosinski EJ, Warram JH et al. (1987) Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750-755
2. Pyörälä K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524
3. Laakso M, Lehto S (1997) Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5:294-315
4. Nathan DM, Meigs J, Singer DE (1997) The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 350 [Suppl I]:SI4-SI9
5. Howard B, Rodriguez BL, Bennet PH et al. (2002) Prevention Conference VI. Diabetes and cardiovascular disease. Writing Group I: Epidemiology. Circulation 105:e132-e137
6. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Ass 287:2570-2581
7. Löwell H, König W, Engel S, Hörmann A, Keil U (2000) The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43:218-226
8. Malmberg K, Yusuf S, Gerstein HC et al. (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 102:1014-1019
9. McGuire DK, Emanuelsson H, Granger CB et al. (2000) Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the Gusto-IIb study. Gusto IIb Investigators. Eur Heart J 21:1750-1758
10. Mukamal KJ, Nesto RW, Cohen MC et al. (2001) Impact of diabetes on long-term survival after acute myocardial infarction: comparability or risk with prior myocardial infarction. Diabetes Care 24:1422-1427
11. Laskey WK, Selzer F, Vlachos HA et al. (2002) Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 90:1062-1067
12. Norhammar A, Tenerz A, Nilsson G et al. (2002) Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140-2144
13. Herlitz J, Wognsen GB, Karlson BW et al. (2000) Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis 11:339-346
14. Pyörälä K, Pedersen T, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival Study (4S) Group (1997) Cholesterol lowering improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620
15. Goldberg RB, Mellies MJ, Sacks FM et al., for the CARE Investigators (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 98:2513-2519
16. Keech A, Colquhoun D, Best J et al. for the LIPID Study Group (2003) Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired glucose tolerance. Diabetes Care 26:2713-2721
17. Rubins HB, Robins SJ, Collins D et al. (1999) Gemfibrozil for secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
18. Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes. Lancet 361:2005-2016
19. Curb JD, Pressel SL, Cutler JA et al. (1996) Effect of diuretic-based anti-hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. J Am Med Ass 276:1886-1892
20. Hansson L, Zanchetti A, Carruthers SG et al. for the HOT Study Group (1998) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762
21. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. (1999) Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340:677-684
22. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 324:71-86
23. Gundersen T, Kjekshus J (1983) Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 6:285-290
24. Moye LA, Pfeffer MA, Wun CC et al., for the SAVE Investigators (1994) Uniformity of captopril benefit in the SAVE subgroup analysis. Eur Heart J 15:2-8
25. Torp-Pedersen C, Kober L, Carlsen J, on behalf of the TRACE Study Group (1996) Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation study. Am Heart J 132:235-243
26. Zuanetti G, Latini R, Maggioni M, Santoro L, Tognoni G, on behalf of the GISSI-3 Investigators (1997) Effect of the ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: the data from the GISSI-3 study. Circulation 96:4239-4245
27. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
28. Pyörälä K, De Backer G, Graham I, Poole-Wilson PA, Wood DA, on behalf of the Task Force (1994) Prevention of coronary heart disease in clinical practice. Recommendations of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15:1300-1331
29. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K together with members of the Task Force (1998) Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task of European and other Societies on Coronary Prevention. Eur Heart J 19:1434-1503
30. De Backer G, Ambrosioni E, Borch-Johnsen K et al. (2003) Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24:1601-1610
31. EUROASPIRE Study Group (1997) EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 18:1569-1582
32. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients in 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 22:554-572
33. EUROASPIRE I and II Group (2001) Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 357:995-1001
34. Report of a WHO Consultation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization (WHO/NCD/NCS/99.2), Geneva
35. Hsu JC (1996) Multiple comparisons: theory and methods. Chapman & Hall, London
36. Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 17:873-890
37. The DECODE-study group on behalf of the European Diabetes Epidemiology Group (1999) Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 42:647-654
38. American Diabetes Association (2003) Clinical practice recommendations 2003. Diabetes Care 26 [Suppl 1]:S1-S156